Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16963735 | 1.00 | APLNR (0.32) | APLNR | |
| SCHEMBL16964790 | 1.00 | APLNR (0.32) | APLNR | |
| SCHEMBL22124454 | 0.82 | GAA (0.35) | — | |
| SCHEMBL16521086 | 0.82 | GAA (0.35) | — | |
| SCHEMBL22468894 | 0.75 | RAB9A (0.37) | — | |
| SCHEMBL16521083 | 0.74 | SOAT1 (0.33) | — | |
| SCHEMBL22124447 | 0.73 | SOAT1 (0.31) | — | |
| SCHEMBL22124328 | 0.73 | SOAT1 (0.31) | — | |
| SCHEMBL22124275 | 0.73 | SOAT1 (0.31) | — | |
| SCHEMBL22124326 | 0.73 | SOAT1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| US-11834391-B2 | Pantothenamide analogues | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2023-12-05 | — | — | US | disclosed |
| EP-3906225-B1 | PANTOTHENAMIDE ANALOGUES | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-20230159437-A1 | PANTOTHENAMIDE ANALOGUES | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2023-05-25 | — | — | US | disclosed |
| US-11572336-B2 | Pantothenamide analogues | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2023-02-07 | — | — | US | disclosed |
| US-20220073450-A1 | PANTOTHENAMIDE ANALOGUES | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2022-03-10 | — | — | US | disclosed |
| EP-3906225-A1 | PANTOTHENAMIDE ANALOGUES | MMV Medicines for Malaria Venture (CH) | 2021-11-10 | — | — | EP | disclosed |
| WO-2020141155-A1 | PANTOTHENAMIDE ANALOGUES | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2020-07-09 | — | — | WO | disclosed |
| US-20030236213-A1 | Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses | ESPERION THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
| WO-2003087040-A2 | MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572336-B2 | Pantothenamide analogues | NAMPT, VKORC1, NME4 | APLNR 2791/4885 |
| US-20220073450-A1 | PANTOTHENAMIDE ANALOGUES | NAMPT, VKORC1, NME4 | APLNR 2791/4885 |
| US-20030236213-A1 | Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses | COASY, HMGCR, ACACA | APLNR 328/4885 |
| US-11834391-B2 | Pantothenamide analogues | NAMPT, VKORC1, NME4 | APLNR 2791/4885 |
| US-20230159437-A1 | PANTOTHENAMIDE ANALOGUES | NAMPT, VKORC1, NME4 | APLNR 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.